Time to Treat: Applying Lessons Learned from Other Viral Syndromes to SARS-CoV-2.
Mayo Clin Proc Innov Qual Outcomes
; 4(6): 759-763, 2020 Dec.
Article
in English
| MEDLINE | ID: covidwho-846261
ABSTRACT
In many different infectious syndromes, most notably several viral conditions, time to therapy initiation from symptom onset has been identified as a critical component contributing to the success of therapy. Regarding COVID-19, several therapeutic antivirals, both repurposed and novel, have been evaluated for overall safety and efficacy. As the literature related to these therapies has expanded recently, a wide array of trial designs, time to therapy initiation thresholds, and clinical outcomes in regard to time to initiation have been reported. We describe the potential effects of time to therapy initiation on outcomes in patients with COVID-19 and detail the existing data surrounding this topic in relation to remdesivir, convalescent plasma, lopinavir/ritonavir, and hydroxychloroquine.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Language:
English
Journal:
Mayo Clin Proc Innov Qual Outcomes
Year:
2020
Document Type:
Article
Affiliation country:
J.mayocpiqo.2020.09.010
Similar
MEDLINE
...
LILACS
LIS